THE BURAN STUDY OF BUPARLISIB (AN2025) IN COMBINATION WITH PACLITAXEL COMPARED TO PACLITAXEL ALONE, IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA.
- Registry ID
- AN2025H0301
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- ADLAI NORTYE USA INC
- Start date
- 2024-04-13
- Completion date
- 2025-11-02
- Last update
- 2020-05-26
Conditions
- CARCINOMA OF THE HEAD AND NECK
Related clinical trials
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY OF FICERAFUSP ALFA
(BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST LINE
TREATMENT OF PD-L1-POSITIVE, RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS
CELL CARCINOMA
- A RANDOMIZED, PHASE 2, OPEN-LABEL, MULTI-ARM STUDY OF TISLELIZUMAB IN
COMBINATION WITH INVESTIGATIONAL AGENTS AS FIRST-LINE TREATMENT IN PATIENTS
WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
- INTRATYMPANIC N-ACETYLCYSTEINE (NAC) INJECTIONS FOR PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY IN HEAD AND NECK CANCER PATIENTS: A MULTI-CENTRE PHASE II RANDOMIZED CONTROLLED TRIAL.
- "A PHASE II, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 MONOTHERAPY, TREMELIMUMAB MONOTHERAPY, AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)."
- A PHASE 3 CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN FIRST LINE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
- RANDOMIZED CONTROLLED TRIAL TO TEST THE EFFICACY OF TRANS-TYMPANIC INJECTIONS OF A SODIUM THIOSULFATE GEL TO PREVENT CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH HEAD AND NECK CANCER
View on source registry